Research programme: BET inhibitors - Zenith Epigenetics CorpAlternative Names: NexVas Autoimmune (AI) programme - Resverlogix; NexVas vascular inflammation; NexVas VI (vascular inflammation) therapy - Resverlogix; RVX-297
Latest Information Update: 24 Sep 2014
At a glance
- Originator Resverlogix Corporation; Zenith Epigenetics Corp
- Developer Zenith Epigenetics Corp
- Class Small molecules
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders
- Research Cancer